A Narrative Review on Osteogenesis Imperfecta and Its Management

Year : 2024 | Volume :02 | Issue : 01 | Page : 1-10

Asad Jamal Ansari,

Guisia Khan,

Kudshiya Khan,

  1. Faculty Integral University Uttar Pradesh India
  2. Researcher Integral University Uttar Pradesh India
  3. Researcher Integral University Uttar Pradesh India


Osteogenesis imperfecta (OI), sometimes referred to as brittle bone disease, is a heterogeneous illness characterized by short stature, several fractures, and distorted bones. The main contributing factor to OI is mutations in the genes needed to produce type 1 collagen. While severe OI is perinatally fatal, mild OI can occasionally not be detected until maturity. The frequency of Osteogenesis imperfecta ranges from about 1:15,000 to 1:20,000 births. Five kinds of the illness are commonly differentiated, ranging in severity from moderate (type I) to deadly (type II). Types III and IV are serious types that permit survival during the newborn period, but type V has a mild to moderate phenotype and interosseous membrane calcification. The majority of the time, mutations in the col I genes result in a decrease in the production of common type I collagen (col I) or the synthesis of uncommon collagen. Moreover, it has been shown that mutations in the genes responsible for osteoblast development, col I processing, and synthesis have occurred. The objective of this study is to review the research on the current medical treatments for osteogenesis imperfecta (OI) in patients. The treatments that are currently available aim to reduce or eliminate symptoms, prevent fractures, and build bone mass. Medications like bisphosphonates, denosumab, and teriparatide are frequently used to treat OI.

Keywords: Osteogenesis imperfecta, bisphosphonates, denosumab, teriparatide, physiotherapy

[This article belongs to International Journal of Orthopedic Nursing and Practices(ijornp)]

How to cite this article: Asad Jamal Ansari, Guisia Khan, Kudshiya Khan. A Narrative Review on Osteogenesis Imperfecta and Its Management. International Journal of Orthopedic Nursing and Practices. 2024; 02(01):1-10.
How to cite this URL: Asad Jamal Ansari, Guisia Khan, Kudshiya Khan. A Narrative Review on Osteogenesis Imperfecta and Its Management. International Journal of Orthopedic Nursing and Practices. 2024; 02(01):1-10. Available from: https://journals.stmjournals.com/ijornp/article=2024/view=148709


  1. Gupte S. Differential Diagnosis in Pediatrics:(Including Color Atlas). Jaypee Brothers Medical Publishers; 2019 Jul 31
  2. Mortier GR, Cohn DH, Cormier‐Daire V, Hall C, Krakow D, Mundlos S, Nishimura G, Robertson S, Sangiorgi L, Savarirayan R, Sillence D. Nosology and classification of genetic skeletal disorders: 2019 revision. Am JMed Genet 2019 Dec; 179(12): 2393–419.
  3. Sillence D, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979 Apr 1; 16(2): 101–
  4. Van Dijk FS, Sillence DO. Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. AmJ Med Genet 2014 Jun; 164(6): 1470–81.
  5. Chetty M, Roomaney IA, Beighton P. The evolution of the nosology of osteogenesis imperfecta. Clin Genet. 2021 Jan; 99(1): 42–
  6. Ango S, Fatunke ET, Jemide OO. Osteogenesis Imperfecta in a Newborn: Case Report and Review of the Literature. Nigerian Journal of Perinatal and Neonatal Care (NJPNC). 2023 Mar 14; 3(1): 40–6.
  7. Marom R, Rabenhorst BM, Morello R. Management of endocrine disease: Osteogenesis imperfecta: An update on clinical features and therapies. Eur J Endocrinol. 2020 Oct 1; 183(4): R95–
  8. Bregou Bourgeois A, Aubry-Rozier B, Bonafé L, Laurent-Applegate LA, Pioletti D, Zambelli PY. Osteogenesis imperfecta: from diagnosis and multidisciplinary treatment to future perspectives. Swiss Med W 2016; 146:w14322.
  9. Forlino A, Marini JC. Osteogenesis imperfecta. 2016 Apr 16; 387(10028): 1657–71.
  10. Götherström C, Westgren M, Shaw SS, Åström E, Biswas A, Byers PH, Mattar CN, Graham GE, Taslimi J, Ewald U, Fisk NM. Pre-and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience. Stem Cells Transl Med. 2014 Feb 1; 3(2): 255–
  11. Sillence D, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979 Apr 1; 16(2): 101–
  12. Bardai G, Moffatt P, Glorieux FH, Rauch F. DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum. Osteopor Int. 2016 Dec; 27(12): 3607–
  13. Robinson ME, Rauch F. Mendelian bone fragility disorders. Bone. 2019 Sep 1; 126: 11–
  14. Marini JC, Cabral WA. Osteogenesis imperfecta. Genetics of bone biology and skeletal disease. 2018 Jan 1: 397–
  15. Cheung MS, Glorieux FH, Rauch F. Natural history of hyperplastic callus formation in osteogenesis imperfecta type V. J Bone Miner Res. 2007 Aug; 22(8): 1181–
  16. Marr C, Seasman A, Bishop N. Managing the patient with osteogenesis imperfecta: a multidisciplinary approach. JMultidiscip Healthc. 2017 Apr 4; 10: 145–
  17. Bains JS, Carter EM, Citron KP, Boskey AL, Shapiro JR, Steiner RD, Smith PA, Bober MB, Hart T, Cuthbertson D, Krischer J. A multicenter observational cohort study to evaluate the effects of bisphosphonate exposure on bone mineral density and other health outcomes in osteogenesis imperfecta. JBMR Plus. 2019 May; 3(5):
  18. Lv F, Liu Y, Xu X, Song Y, Li L, Jiang Y, Wang O, Xia W, Xing X, Li M. Zoledronic acid versus alendronate in the treatment of children with osteogenesis imperfecta: a 2-year clinical study. Endocr Pract. 2018 Feb 1; 24(2): 179–
  19. Li LJ, Zheng WB, Zhao DC, Yu W, Wang O, Jiang Y, Xia WB, Li M. Effects of zoledronic acid on vertebral shape of children and adolescents with osteogenesis imperfecta. Bone. 2019 Oct 1; 127: 164–
  20. Sillence DO, Rimoin DL, Danks DM. Clinical variability in osteogenesis imperfecta-variable expressivity or genetic heterogeneity. Birth Defects Orig Artic Ser. 1979 Jan 1; 15(5B): 113–
  21. Sillence D, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979 Apr 1; 16(2): 101–
  22. Sillence D, Rimoin D. Classification of osteogenesis imperfecta. 1978 May 13; 311(8072): 1041–2.
  23. McAllion SJ, Paterson CR. Causes of death in osteogenesis imperfecta. J Clin Pathol. 1996 Aug 1; 49(8):627–
  24. Thibeault DW, Pettett G, Mabry SM, Rezaiekhaligh MM. Osteogenesis imperfecta Type IIA and pulmonary hypoplasia with normal alveolar development. Pediatr Pulmonol. 1995 Nov; 20(5): 301–
  25. Sykes B, Wordsworth P, Ogilvie D, Anderson J, Jones N. Osteogenesis imperfecta is linked to both type I collagen structural genes. 1986 Jul 12; 328(8498): 69–72.
  26. Morello R, Bertin TK, Chen Y, Hicks J, Tonachini L, Monticone M, Castagnola P, Rauch F, Glorieux FH, Vranka J, Bächinger HP. CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell. 2006 Oct 20; 127(2): 291–
  27. Barnes AM, Chang W, Morello R, Cabral WA, Weis M, Eyre DR, Leikin S, Makareeva E, Kuznetsova N, Uveges TE, Ashok A. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. New Engl JMed. 2006 Dec 28; 355(26): 2757–
  28. Cabral WA, Chang W, Barnes AM, Weis M, Scott MA, Leikin S, Makareeva E, Kuznetsova NV, Rosenbaum KN, Tifft CJ, Bulas DI. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet. 2007 Mar; 39(3): 359–
  29. Barnes AM, Carter EM, Cabral WA, Weis M, Chang W, Makareeva E, Leikin S, Rotimi CN, Eyre DR, Raggio CL, Marini JC. Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding. New Engl J Med. 2010 Feb 11; 362(6): 521–
  30. van Dijk FS, Nesbitt IM, Zwikstra EH, Nikkels PG, Piersma SR, Fratantoni SA, Jimenez CR, Huizer M, Morsman AC, Cobben JM, van Roij MH. PPIB mutations cause severe osteogenesis imperfecta. Am J HumGenet. 2009 Oct 9; 85(4): 521–
  31. Baldridge D, Schwarze U, Morello R, Lennington J, Bertin TK, Pace JM, Pepin MG, Weis M, Eyre DR, Walsh J, Lambert D. CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta. Hum Mutat. 2008 Dec; 29(12): 1435–
  32. Alanay Y, Avaygan H, Camacho N, Utine GE, Boduroglu K, Aktas D, Alikasifoglu M, Tuncbilek E, Orhan D, Bakar FT, Zabel B. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am J Hum Genet. 2010 Apr 9; 86(4): 551–
  33. Kelley BP, Malfait F, Bonafe L, Baldridge D, Homan E, Symoens S, Willaert A, Elcioglu N, Van Maldergem L, Verellen‐Dumoulin C, Gillerot Y. Mutations in FKBP10 cause recessive osteogenesis imperfecta and Bruck syndrome. JBone Miner Res. 2011 Mar; 26(3): 666–
  34. Christiansen HE, Schwarze U, Pyott SM, AlSwaid A, Al Balwi M, Alrasheed S, Pepin MG, Weis MA, Eyre DR, Byers PH. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am J Hum Genet. 2010 Mar 12; 86(3): 389–
  35. Becker J, Semler O, Gilissen C, Li Y, Bolz HJ, Giunta C, Bergmann C, Rohrbach M, Koerber F, Zimmermann K, de Vries P. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet. 2011 Mar 11; 88(3): 362–
  36. Homan EP, Rauch F, Grafe I, Lietman C, Doll JA, Dawson B, Bertin T, Napierala D, Morello R, Gibbs R, White L. Mutations in SERPINF1 cause osteogenesis imperfecta type VI. J Bone Miner Res. 2011 Dec; 26(12):2798–
  37. Lapunzina P, Aglan M, Temtamy S, Caparrós-Martín JA, Valencia M, Letón R, Martínez-Glez V, Elhossini R, Amr K, Vilaboa N, Ruiz-Perez VL. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. Am J Hum Genet. 2010 Jul 9; 87(1): 110–
  38. Martínez‐Glez V, Valencia M, Caparrós‐Martín JA, Aglan M, Temtamy S, Tenorio J, Pulido V, Lindert U, Rohrbach M, Eyre D, Giunta C. Identification of a mutation causing deficient BMP1/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta. Hum Mutat. 2012 Feb; 33(2): 343–
  39. Laine CM, Joeng KS, Campeau PM, Kiviranta R, Tarkkonen K, Grover M, Lu JT, Pekkinen M, Wessman M, Heino TJ, Nieminen-Pihala V. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. New Engl JMed. 2013 May 9; 368(19): 1809–
  40. Cho TJ, Lee KE, Lee SK, Song SJ, Kim KJ, Jeon D, Lee G, Kim HN, Lee HR, Eom HH, Lee ZH. A single recurrent mutation in the 5′-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet. 2012 Aug 10; 91(2): 343–
  41. Shapiro JR, Lietman C, Grover M, Lu JT, Nagamani SC, Dawson BC, Baldridge DM, Bainbridge MN, Cohn DH, Blazo M, Roberts TT. Phenotypic variability of osteogenesis imperfecta type V caused by an IFITM5 mutation. J Bone Miner Res. 2013 Jul; 28(7): 1523–
  42. Shaheen R, Alazami AM, Alshammari MJ, Faqeih E, Alhashmi N, Mousa N, Alsinani A, Ansari S, Alzahrani F, Al-Owain M, Alzayed ZS. Study of autosomal recessive osteogenesis imperfecta in Arabia reveals a novel locus defined by TMEM38B mutation. J Med Genet. 2012 Oct 1; 49(10): 630–
  43. Volodarsky M, Markus B, Cohen I, Staretz‐Chacham O, Flusser H, Landau D, Shelef I, Langer Y, Birk OS. A Deletion Mutation in TMEM 38 B Associated with Autosomal Recessive Osteogenesis Imperfecta. Hum Mutat. 2013 Apr;34(4): 582–
  44. van Dijk FS, Zillikens MC, Micha D, Riessland M, Marcelis CL, de Die-Smulders CE, Milbradt J, Franken AA, Harsevoort AJ, Lichtenbelt KD, Pruijs HE. PLS3 mutations in X-linked osteoporosis with fractures. New Engl J Med. 2013 Oct 17; 369(16): 1529–
  45. Symoens S, Malfait F, D’hondt S, Callewaert B, Dheedene A, Steyaert W, Bächinger HP, De Paepe A, Kayserili H, Coucke PJ. Deficiency for the ER-stress transducer OASIS causes severe recessive osteogenesis imperfecta in humans. Orphanet J Rare Dis. 2013 Dec; 8: 1–
  46. Pyott SM, Tran TT, Leistritz DF, Pepin MG, Mendelsohn NJ, Temme RT, Fernandez BA, Elsayed SM, Elsobky E, Verma I, Nair S. WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. Am J Hum Genet. 2013 Apr 4; 92(4): 590–
  47. Pyott SM, Schwarze U, Christiansen HE, Pepin MG, Leistritz DF, Dineen R, Harris C, Burton BK, Angle B, Kim K, Sussman MD. Mutations in PPIB (cyclophilin B) delay type I procollagen chain association and result in perinatal lethal to moderate osteogenesis imperfecta phenotypes. Hum Mol Genet. 2011 Apr 15; 20(8): 1595–
  48. Marini JC, Cabral WA, Barnes AM. Null mutations in LEPRE1 and CRTAP cause severe recessive osteogenesis imperfecta. Cell Tissue Res. 2010 Jan; 339(1): 59–
  49. Marini JC, Blissett AR. New genes in bone development: what’s new in osteogenesis imperfecta. J ClinEndocrinol Metab. 2013 Aug 1; 98(8): 3095–
  50. Byers PH, Pyott SM. Recessively inherited forms of osteogenesis imperfecta. Annu Rev Genet. 2012 Dec 15;46: 475–
  51. Forlino A, Cabral WA, Barnes A, Marini C. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011 Jun 14;7(9): 540–
  52. Marini JC, Forlino A, Cabral WA, Barnes AM, San Antonio JD, Milgrom S, Hyland JC, Körkkö J, Prockop DJ, De Paepe A, Coucke P. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat. 2007 Mar; 28(3):209–
  53. Forlino A, Marini JC. Osteogenesis imperfecta. 2016 Apr 16; 387(10028): 1657–71.
  54. Viguet-Carrin S, Garnero P, Delmas PD. The role of collagen in bone strength. Osteoporos Int. 2006 Mar; 17(3):319–
  55. Rauch F, Lalic L, Roughley P, Glorieux FH. Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. J Bone Miner Res. 2010 Jun; 25(6): 1367–
  56. Willing MC, Deschenes SP, Slayton RL, Roberts EJ. Premature chain termination is a unifying mechanism for COL1A1 null alleles in osteogenesis imperfecta type I cell strains. Am J Hum Genet. 1996 Oct; 59(4): 799–809.
  57. Hoyer-Kuhn H, Semler O, Schoenau E. Effect of denosumab on the growing skeleton in osteogenesis imperfecta. J Clin Endocrinol Metab. 2014 Nov 1; 99(11): 3954–
  58. Marom R, Lee YC, Grafe I, Lee B. Pharmacological and biological therapeutic strategies for osteogenesis imperfecta. InAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2016 Dec; 172(4): 367–383.
  59. Krakow D. Skeletal dysplasias. Clin Perinatol. 2015 Jun 1; 42(2): 301–
  60. Pagon RA, Bird TD, Dolan CR, Stephens K, Waters AM, Beales PL. Bardet–Biedl syndrome. GeneReviews (®).Seattle, WA: University of Washington, Seattle;
  61. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. New Engl J Med. 1998 Oct 1; 339(14): 947–
  62. Phillipi CA, Remmington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2008; (4).
  63. Marini JC, Hopkins E, Glorieux FH, Chrousos GP, Reynolds JC, Gundberg CM, Reing CM. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen. J Bone Miner Res. 2003 Feb; 18(2):237–
  64. van Dijk FS, Cobben JM, Kariminejad A, Maugeri A, Nikkels PG, van Rijn RR, Pals G. Osteogenesis imperfecta: a review with clinical examples. Mol Syndromol. 2011 Dec 1; 2(1): 1–
  65. Narayanan P. Denosumab: A comprehensive review. South Asian J 2013 Oct; 2(04): 272–7.
  66. Li G, Jin Y, Levine MA, Hoyer‐Kuhn H, Ward L, Adachi JD. Systematic review of the effect of denosumab on children with osteogenesis imperfecta showed inconsistent findings. Acta Paediatr. 2018 Mar; 107(3): 534–
  1. Hoyer-Kuhn H, Franklin J, Allo G, Kron M, Netzer C, Eysel P, Hero B, Schoenau E, Semler O. Safety and efficacy of denosumab in children with osteogenesis imperfecta-a first prospective trial. J Musculoskelet Neuronal Interact. 2016 Mar; 16(1): 24–32.
  2. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017 Jul 1;5(7): 513–
  3. Morello R. Osteogenesis imperfecta and therapeutics. Matrix Biol. 2018 Oct 1; 71: 294–
  4. Orwoll ES, Shapiro J, Veith S, Wang Y, Lapidus J, Vanek C, Reeder JL, Keaveny TM, Lee DC, Mullins MA, Nagamani SC. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Investig. 2014 Feb 3; 124(2): 491–
  5. Leali PT, Balsano M, Maestretti G, Brusoni M, Amorese V, Ciurlia E, Andreozzi M, Caggiari G, Doria C. Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study. Clin Cases Miner Bone Metab. 2017 May; 14(2): 153–156.
  6. Gatti D, Rossini M, Viapiana O, Povino MR, Liuzza S, Fracassi E, Idolazzi L, Adami S. Teriparatide treatment in adult patients with osteogenesis imperfecta type I. Calcif Tissue Int. 2013 Nov; 93(5): 448–
  7. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Ma YL, Nold JB. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002 Apr; 30(3): 312–
  8. Besio R, Forlino A. New frontiers for dominant osteogenesis imperfecta treatment: gene/cellular therapy approaches. Advances in Regenerative Biology (ARB). 2015 Jan 1; 2(1):
  9. Guillot PV, Abass O, Bassett JD, Shefelbine SJ, Bou-Gharios G, Chan J, Kurata H, Williams GR, Polak J, Fisk NM. Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice. Blood, The Journal of the American Society of Hematology. 2008 Feb 1; 111(3):1717–
  10. Panaroni C, Gioia R, Lupi A, Besio R, Goldstein SA, Kreider J, Leikin S, Vera JC, Mertz EL, Perilli E, Baruffaldi F. In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knock in murine model for classical, dominant osteogenesis imperfecta. Blood, The Journal of the American Society of Hematology. 2009 Jul 9; 114(2): 459–
  11. Sinder BP, Novak S, Wee NK, Basile M, Maye P, Matthews BG, Kalajzic I. Engraftment of skeletal progenitor cells by bone-directed transplantation improves osteogenesis imperfecta murine bone phenotype. Stem Cells. 2020 Apr 1; 38(4):530–
  12. Wirth T. The orthopaedic management of long bone deformities in genetically and acquired generalized bone weakening conditions. J Child Orthop. 2019 Feb; 13(1): 12–
  13. Binder H, Conway A, Gerber LH. Rehabilitation approaches to children with osteogenesis imperfecta: a ten-year experience. Arch Phys Med Rehabil. 1993 Apr 1; 74(4): 386–
  14. Binder H, Conway A, Hason S, Gerber LH, Marini J, Berry R, Weintrob J. Comprehensive rehabilitation of the child with osteogenesis imperfecta. Am J Med Genet. 1993 Jan 15; 45(2): 265–
  15. Mueller B, Engelbert R, Baratta-Ziska F, Bartels B, Blanc N, Brizola E, Fraschini P, Hill C, Marr C, Mills L, Montpetit K. Consensus statement on physical rehabilitation in children and adolescents with osteogenesis imperfecta. Orphanet J Rare Dis. 2018 Dec; 13(1): 158(4p).

Regular Issue Subscription Review Article
Volume 02
Issue 01
Received May 10, 2024
Accepted May 22, 2024
Published May 29, 2024